Investigational drug · Phase 3
SIM0270
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "SIM0270"
First trial start
2024
Nov 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SIM0270", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SIM0270" as an intervention, largest first.
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Pivotal-lookingActive, not recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT06680921 · 482 participants · Start Nov 14, 2024 · Primary completion Aug 31, 2028
Drug: SIM0270; Everolimus (Afinitor®) and 2 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Bengbu, China; Hefei, China; Maanshan, China · 57 sites in all
- Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerActive, not recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT05293964 · 214 participants · Start May 18, 2022 · Primary completion Dec 31, 2024
Drug: SIM0270; Palbociclib and 1 more · For: Breast Cancer
Sites: Shanghai, China
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07357610 · 60 participants (planned) · Start Jan 5, 2026 · Primary completion Oct 30, 2026
Drug: SIM0270; itraconazole and 2 more · For: Healthy Adult Participants
Sites: Jinan, China
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT06536036 · 16 participants · Start Jul 23, 2024 · Primary completion Oct 16, 2024
Drug: SIM0270 · For: Healthy Participants
Sites: Jinan, China
- Mass Balance Clinical Trial of SIM0270Active, not recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT06654791 · 6 participants · Start Oct 17, 2024 · Primary completion Mar 31, 2025
Drug: [14C] SIM0270 Oral Preparation · For: Healthy Participants
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Translational pharmacokinetic/pharmacodynamic modeling to inform target concentration and dose projection of a novel selective estrogen receptor degrader (SIM0270) for early clinical development.
Shi Y, Gu M, Yang Y, et al. · J Pharmacol Exp Ther 2026
Also in development for Locally Advanced or Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- SPH4336Phase 34 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Locally Advanced or Metastatic Breast Cancer, Breast Cancer Brain Metastases, Advanced Solid Tumors
- YL202 should be intravenously infusedPhase 22 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.